Upadhyay Suketu — SEC Form 4 filings
SEC reporting owner CIK 1533149. 23 Form 4 filings on record with FilingPulse; latest filed 2026-05-06.
Transaction summary — filings shown
Covers all 23 filings on record, filed 2024-02-22 to 2026-05-06. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 57.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | Exec VP, CFO | 14 | — | — | 40 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | Director | 8 | — | — | 14 |
| INCYTE CORP (INCY) | EVP & Chief Financial Officer | 1 | — | — | 3 |
Form 4 filings — Upadhyay Suketu
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-06 | 4 | INCYTE CORP (INCY) | Grant/award (A): 26,343 @ $0 · Grant/award (A): 38,429 (derivative) @ $0 · Grant/award (A): 13,171 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Disposition to issuer (D): 796 · Grant/award (A): 2,866 (derivative) @ $0 · Grant/award (A): 796 (derivative) | EDGAR |
| 2026-04-17 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 80.51 (derivative) @ $442.50 | EDGAR |
| 2026-03-10 | 4 | ZIMMER BIOMET HOLDINGS, INC. (ZBH) | Option exercise (M): 10,217 @ $0 · Tax withholding (F): 4,547 @ $92.54 · Option exercise (M): 4,559 @ $0 · Tax withholding (F): 2,029 @ $92.54 · Option exercise (M): 10,217 (derivative) @ $0 · Option exercise (M): 4,559 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | ZIMMER BIOMET HOLDINGS, INC. (ZBH) | Option exercise (M): 6,364 @ $0 · Tax withholding (F): 2,832 @ $99.51 · Option exercise (M): 6,364 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | ZIMMER BIOMET HOLDINGS, INC. (ZBH) | Option exercise (M): 5,445 @ $0 · Tax withholding (F): 2,446 @ $98.62 · Option exercise (M): 5,445 (derivative) @ $0 · Grant/award (A): 21,701 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | ZIMMER BIOMET HOLDINGS, INC. (ZBH) | Grant/award (A): 10,217 (derivative) @ $0 | EDGAR |
| 2026-01-20 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 80.32 (derivative) @ $443.56 | EDGAR |
| 2025-11-12 | 4 | ZIMMER BIOMET HOLDINGS, INC. (ZBH) | Option exercise (M): 10,632 @ $0 · Tax withholding (F): 4,731 @ $87.73 · Option exercise (M): 10,632 (derivative) @ $0 | EDGAR |
| 2025-11-03 | 4 | ZIMMER BIOMET HOLDINGS, INC. (ZBH) | Grant/award (A): 10,632 (derivative) @ $0 | EDGAR |
| 2025-10-17 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 86.83 (derivative) @ $410.31 | EDGAR |
| 2025-07-17 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 75.90 (derivative) @ $469.34 | EDGAR |
| 2025-05-05 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 796 @ $0 · Disposition to issuer (D): 1,001 · Grant/award (A): 1,001 (derivative) | EDGAR |
| 2025-04-17 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 71.61 (derivative) @ $497.51 | EDGAR |
| 2025-03-07 | 4 | ZIMMER BIOMET HOLDINGS, INC. (ZBH) | Option exercise (M): 4,560 @ $0 · Tax withholding (F): 2,029 @ $104.86 · Option exercise (M): 4,560 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | ZIMMER BIOMET HOLDINGS, INC. (ZBH) | Grant/award (A): 19,090 (derivative) @ $0 | EDGAR |
| 2025-02-24 | 4 | ZIMMER BIOMET HOLDINGS, INC. (ZBH) | Option exercise (M): 5,446 @ $0 · Tax withholding (F): 2,423 @ $103.46 · Option exercise (M): 5,446 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | ZIMMER BIOMET HOLDINGS, INC. (ZBH) | Option exercise (M): 21,622 @ $0 · Tax withholding (F): 8,155 @ $101 · Grant/award (A): 21,622 (derivative) @ $0 · Option exercise (M): 21,622 (derivative) @ $0 | EDGAR |
| 2024-11-12 | 4 | ZIMMER BIOMET HOLDINGS, INC. (ZBH) | Option exercise (M): 15,948 @ $0 · Tax withholding (F): 7,097 @ $108.48 · Grant/award (A): 15,948 (derivative) @ $0 · Option exercise (M): 15,948 (derivative) @ $0 | EDGAR |
| 2024-05-03 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 1,001 @ $0 · Disposition to issuer (D): 1,168 · Grant/award (A): 1,168 (derivative) | EDGAR |
| 2024-03-08 | 4 | ZIMMER BIOMET HOLDINGS, INC. (ZBH) | Option exercise (M): 4,561 @ $0 · Tax withholding (F): 1,919 @ $125.82 · Option exercise (M): 4,561 (derivative) @ $0 | EDGAR |
| 2024-02-27 | 4 | ZIMMER BIOMET HOLDINGS, INC. (ZBH) | Option exercise (M): 7,043 @ $0 · Tax withholding (F): 2,091 @ $128.80 · Option exercise (M): 7,043 (derivative) @ $0 | EDGAR |
| 2024-02-22 | 4 | ZIMMER BIOMET HOLDINGS, INC. (ZBH) | Grant/award (A): 16,336 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1533149 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →